innovation highlight
New drugs and therapies for spinal cord injuries
Despite advances in modern medicine, there is still no cure for paraplegia. The central nervous system reacts to the damage to nerve and connectivetissue cells by forming a collagen scar. Neuraxo Biopharmaceuticals GmbH has found evidence that collagen scar formation is the main inhibiting factor to regenerative growth of nerve fibers in the central nervous system, and has developed a highly innovative neurotherapeutic method to prevent local formation of this regenerationinhibiting scar tissue for a sufficiently long time to allow recovery.
Regenerating nerve fibers after RPT-application
If scar formation is suppressed for a few weeks after the accident, the nerve cells are able to grow back over the site of the injury and reconnect with a func-tioning nerve tract. Neuraxo calls its patented platform technology Regeneration Promoting Treatment (RPT).
For the first clinical application of RPT, Neuraxo is focusing on the development Cordaneurin®, a drug for the treatment of acute spinal cord injuries which was granted Orphan Drug status in 2004. Cordaneurin® has already proven its efficacy in preclinical studies, sustainably restoring motor and sensory functions. The first human clinical trials of Cordaneurin® will be conducted in 2006.
Source: BioRiver - Life Science im Rheinland e.V.
Region: Rhine Ruhr Sieg
Print page
Back
